Extension of indication for Kymriah, to include treatment of
adult patients with follicular lymphoma (FL)
after two or more lines of therapy who are
refractory, or relapsed during or within 6
months after completion of anti -CD20 antibody
maintenance, or relapsed after autologous haematopoietic stem cell transplantation (HSCT) .